113 related articles for article (PubMed ID: 7211966)
1. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes.
Albrecht BH; Schiff I; Tulchinsky D; Ryan KJ
Am J Obstet Gynecol; 1981 Mar; 139(6):631-5. PubMed ID: 7211966
[TBL] [Abstract][Full Text] [Related]
2. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
de Greef WJ; Dullaart J; Zeilmaker GH
J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
[TBL] [Abstract][Full Text] [Related]
3. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes.
Hammond MG; Hatley L; Talbert LM
J Clin Endocrinol Metab; 1984 Jun; 58(6):1158-60. PubMed ID: 6725512
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of the surgical menopause syndrome with depot medroxyprogesterone acetate and its objective evaluation testing the reaction of the anterior pituitary gland to stimulation with gonadotropin-releasing hormone].
Boschitsch E; Gitsch E; Spona J
Wien Klin Wochenschr; 1983 Oct; 95(20):718-24. PubMed ID: 6229096
[TBL] [Abstract][Full Text] [Related]
5. A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles.
Cooper AJ; Sandhu S; Losztyn S; Cernovsky Z
Can J Psychiatry; 1992 Dec; 37(10):687-93. PubMed ID: 1473073
[TBL] [Abstract][Full Text] [Related]
6. The effect of contraceptive steroids on hypothalamic-pituitary function.
Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of action of an antifertility vaccine in the rhesus monkey: reversal of the effects of antisera to the beta-subunit of ovine luteinizing hormone by medroxyprogesterone acetate.
Thau RB; Sundaram K
Fertil Steril; 1980 Mar; 33(3):317-20. PubMed ID: 6767627
[TBL] [Abstract][Full Text] [Related]
8. Oral medroxyprogesterone in the treatment of postmenopausal symptoms.
Schiff I; Tulchinsky D; Cramer D; Ryan KJ
JAMA; 1980 Sep; 244(13):1443-5. PubMed ID: 6775094
[TBL] [Abstract][Full Text] [Related]
9. Differences in the ratio of bioactive to immunoreactive serum luteinizing hormone during vasomotor flushes and hormonal therapy in postmenopausal women.
Chang SP; Shoupe D; Kletzky OA; Lobo RA
J Clin Endocrinol Metab; 1984 May; 58(5):925-9. PubMed ID: 6323519
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
11. The use of medroxyprogesterone acetate for relief of climacteric symptoms.
Morrison JC; Martin DC; Blair RA; Anderson GD; Kincheloe BW; Bates GW; Hendrix JW; Rivlin ME; Forman EK; Propst MG; Needham R
Am J Obstet Gynecol; 1980 Sep; 138(1):99-104. PubMed ID: 7416212
[TBL] [Abstract][Full Text] [Related]
12. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
Ganzina F
Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
[TBL] [Abstract][Full Text] [Related]
13. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
[TBL] [Abstract][Full Text] [Related]
14. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
15. Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma.
Aslaksen K; Frankendal B
Acta Obstet Gynecol Scand; 1982; 61(5):423-8. PubMed ID: 6760653
[TBL] [Abstract][Full Text] [Related]
16. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
[TBL] [Abstract][Full Text] [Related]
17. Grwoth hormone, prolactin, and cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with medroxyprogesterone acetate.
Concannon P; Altszuler N; Hampshire J; Butler WR; Hansel W
Endocrinology; 1980 Apr; 106(4):1173-7. PubMed ID: 6444575
[TBL] [Abstract][Full Text] [Related]
18. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
[TBL] [Abstract][Full Text] [Related]
19. Sebum production and plasma testosterone levels in man after high-dose medroxyprogesterone acetate treatment and androgen administration.
Novak E; Hendrix JW; Chen TT; Seckman CE; Royer GL; Pochi PE
Acta Endocrinol (Copenh); 1980 Oct; 95(2):265-70. PubMed ID: 6449127
[TBL] [Abstract][Full Text] [Related]
20. Effect of 6-alpha-methyl-17-alpha-hydroxyprogesterone on urinary excretion of luteinizing hormone.
Mishell DR
Am J Obstet Gynecol; 1967 Sep; 99(1):86-90. PubMed ID: 6034976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
